



Domino synthesis of pyrimido and imidazoquinazolinones

Walid Fathalla¹ | Eman Y. Nofal¹ | Mohamed Abd El-Moneim²

¹Physics and Mathematical Engineering Department, Faculty of Engineering, Port Said University, Port Said, Egypt

²Chemistry Department, Faculty of Science, Port Said University, Port Said, Egypt

Correspondence

Walid Fathalla, Physics and Mathematical Engineering Department, Faculty, Port Said University, Port Said, Egypt.
Email: walid3369@yahoo.com

Abstract

A simple method for the synthesis of *N*-alkyl-2-arylquinazolin-4-amines, methyl 4-((2-arylquinazolin-4-yl)amino) butanoates, 6-aryl-2,3-dihydro-4*H*-pyrimido[1,2-*c*]quinazolin-4-ones, and 5-arylimidazo[1,2-*c*]quinazolin-3(2*H*)-ones has been described. It involves a simple reaction of *N*-(2-cyanophenyl)-substitutedbenzimidoyl chlorides with alkylamine, γ -aminobutyric acid, β -alanine, *L*-alanine, and glycine methyl esters hydrochloride in acetonitrile to afford the desired compounds after a series of instantaneous reactions that include Dimroth rearrangement. The reaction involves reflux for 12 hours, simple addition of reagents to an in situ generated benzimidoyl chloride, and simple workup, to form 21 examples of pure compounds in high yields. The active intermediate *N*-(2-cyanophenyl)-substitutedbenzimidoyl chlorides were formed by the reaction of *N*-(2-cyanophenyl)-substitutedbenzamidides with thionyl chloride in a *one-pot* strategy. The alternative method described for this preparation deals with an exhausting multistep reactions starting from anthranilic acid.

1 | INTRODUCTION

Domino synthesis is a growing field in organic chemistry that execute the principles of sustainability (green chemistry). It involves the synthesis of complex structures by the addition of two or more active substrates and the formation or cleavage of two or more bonds in a single operation without isolation of intermediates, minimal time, maximum selectivity, and high atom economy.^[1]

Imidoyl chloride^[2] intermediates are used extensively in organic synthesis because of its increased reactivity. This reactivity is centered around the electrophilic and nucleophilic displacement and elimination of the chloride group. Imidoyl chloride is used in the synthesis of imidates, thioimides, imidoyl cyanides, and imidoyl isothiocyanates by the reaction of imidoyl chloride with alcohols, thiols, amines, and thiocyanates.^[2-6] Several named reactions Gattermann,^[7] Vilsmeier-Haack reaction,^[8] and Houben-Hoesch reaction^[9] use imidoyl chloride to attack arenes and form aryl ketones by Freidal Craft acylation reaction. Also, imidoyl chloride is

used in peptide synthesis via amidine intermediates.^[10] The undo-use of imidoyl chlorides could be due to the following obstacles: imidoyl chloride derivatives are prepared by the reaction of amides with chlorinating agents suffers from the formation of inactive iminium salts. Imidoyl chloride is very reactive and reacts easily with moisture. The chlorine atom of imidoyl chloride could be easily eliminated and leave it in the form of nitrile. Imidoyl chlorides having α -hydrogens could be easily isomerized. These complications make the attempts to isolate and store imidoyl chlorides for long period difficult; therefore, these compounds are prepared in situ without further purifications.

In continuation of our interest in the preparation of complex structures by Domino strategy, we found it interesting to prepare benzimidoyl chlorides as active intermediates and directly use these to prepare a series of *N*-alkyl 2-aryl quinazolin-4-amines, methyl 4-((2-arylquinazolin-4-yl)amino) butanoates, 6-aryl-2,3-dihydro-4*H*-pyrimido [1,2-*c*]quinazolin-4-ones, and 5-arylimidazo[1,2-*c*]quinazolin-3(2*H*)-ones.


2 | DISCUSSION

The target compound *N*-alkyl 2-aryl quinazolin-4-amines could be easily prepared by the reaction of benzyl amine with chloroquinazoline in DMF for at 100°C for 12 hours. This is the most reliable classical method for this preparation; however, this method suffers from two aspects: first, amines used for this reaction should be of high boiling points such as benzyl amine (other amines normally of low boiling point did not give the desired product); second, we realize in Scheme 1 that this reliable method of preparation of chloroquinazoline from anthranilic acid occurs in a five-step sequential reactions and sixth step for the reaction with benzyl amines, Scheme 1.^[11,12]

Following the main definition of domino reaction reveals synthesis of complex structures by the addition of two or more active substrates and the formation or cleavage of two or more bonds in a single operation without isolation of intermediates, minimal time, maximum selectivity, and high atom economy.^[1] We found it interesting to prepare *N*-alkyl-2-arylquinazolin-4-amines **7a-d** and **10b** from the corresponding *N*-(2-cyanophenyl)-substitutedbenzamides **8a-d**. The reaction of *N*-(2-cyanophenyl)-substitutedbenzamides **8a-d** with thionyl chloride at 70°C for 8 hours afforded the in situ generated free benzimidoyl chlorides **9a-d** that was reacted in a one pot strategy with alkyl amines,



benzyl amine, and allyl amine in acetonitrile (ACN) under reflux condition for 12 hours to afford the desired product in 51% to 70% yield, Scheme 2. The major advantages of this protocol are short reaction time, mild condition, simple work up, high yields, pure products based on *one-pot* domino reaction. We should note that the presence of unsubstituted benzamides or chloro-substituted benzamides **8a-d** were selected carefully to facilitate the Dimroth rearrangement and will be explained later.

The identity of *N*-benzyl-2-arylquinazolin-4-amines **7a-d** is based on ¹H and ¹³C NMR spectroscopy and physicochemical analysis beside equivocal synthesis using a classical method from 4-chloro-2-phenylquinazolines **6a-d**. Thus, the ¹H NMR spectrum of **7a** exhibits doublet, and broad singlet signals at δ 5.03 and 6.13 ppm are typically associated with CH₂ and NH groups. The doublet signal of CH₂ group confirms the Dimroth protocol and the location of benzyl substituent at position 4 of the quinazoline ring. The ¹H NMR spectrum of **7a** also exhibits doublet, doublet, multiplet, multiplet, and multiplet signals at δ 8.63, 7.99, 7.75 to 7.70, 7.54 to 7.48, and 7.42 to 7.34 ppm for 14 aromatic protons. The ¹³C NMR spectrum of **7a** reveals signals at δ 159.3, 159.0, 150.1, 138.6, 135.7, 113.9, and 45.7 ppm associated with two C=N groups, four quaternary aromatic carbons, and CH₂ group, respectively.



SCHEME 1 Classical preparation of *N*-benzyl-2-aryl-quinazolin-4-amines **7a-d**

SCHEME 2 Preparation of *N*-alkyl-2-aryl-quinazolin-4-amines **7a-d** and **10b** from *N*-(2-cyanophenyl)-substitutedbenzamides **8a-d** and **8b**, respectively



SCHEME 3 Preparation of methyl 4-((2-arylquinazolin-4-yl)amino) butanoates **11a-d**


Similarly, the reaction of the in situ generated benzimidoyl chlorides **9a-d** with γ -amino butyric acid methyl ester hydrochloride in the presence of triethyl amine in acetonitrile under reflux condition and gave methyl 4-((2-arylquinazolin-4-yl)amino) butanoates **11a-d** in high yields, Scheme 3.

Our next target was the application of this domino protocol to prepare a number of more complex structures; 6-aryl-2,3-dihydro-4*H*-pyrimido[1,2-*c*]quinazolin-4-ones **12a-d** and 5-arylimidazo[1,2-*c*]quinazolin-3(2*H*)-ones **13-14(a-d)**. Thus, the reaction of benzimidoyl chlorides **9a-d** with β -alanine methyl ester hydrochloride in the presence of triethylamine in acetonitrile under reflux condition and gave 6-aryl-2,3-dihydro-4*H*-pyrimido[1,2-*c*]quinazolin-4-ones **12a-d** (Scheme 4), while the reaction of benzimidoyl chlorides **9a-d** with glycine or *L*-alanine methyl ester hydrochloride in the presence of triethyl amine in acetonitrile under reflux condition gave 5-arylimidazo[1,2-*c*]quinazolin-3(2*H*)-one **13a-d** and 5-aryl-2-methylimidazo[1,2-*c*]quinazolin-3(2*H*)-one **14a-d** in excellent yields (Scheme 4).

The identity of 6-aryl-2,3-dihydro-4*H*-pyrimido[1,2-*c*]quinazolin-4-ones **12a-d**, 5-arylimidazo[1,2-*c*]quinazolin-3(2*H*)-ones **13a-d**, and 5-aryl-2-methylimidazo[1,2-*c*]quinazolin-3(2*H*)-ones **14a-d** is based on ¹H and ¹³C

NMR spectroscopy and physicochemical analysis. Thus, the ¹H NMR spectrum of **12a** reveals two triplet signals at δ 4.21 and 2.71 ppm corresponding to two CH₂ groups. The ¹H NMR spectrum also exhibits doublet, triplet, doublet, and multiplet signals at δ 8.68, 7.85, 7.77, and 7.68-7.53 ppm for nine aromatic protons. The ¹H NMR spectrum of **12a** shows the absence of both: the ester methyl group and NH group that suggests the cyclization occurrence. The ¹³C NMR spectrum of **12a** reveals signals at δ 175.4, 157.7153.1, 146.1, 133.8, 119.6, 46.7, and 29.7 ppm associated with C=O, 2C=N, three quaternary aromatic carbons, NCH₂ and CH₂CO, respectively.

The *one pot* domino reaction for the preparation of 5-phenylimidazo[1,2-*c*]quinazolin-3(2*H*)-one (**13a**) could be explained as follows: a first step addition of free glycine methyl ester to imidoyl group carbon and gave the methyl 2-[*N*-(2-cyanophenyl)benzimidamido] acetate I. Next, an intramolecular *N*-addition of the glycine residue NH at the nitrile group to produce methyl 2-(4-imino-2-phenylquinazolin-3(4*H*)-yl) acetate II. The subsequent Dimroth rearrangement via ring opening–ring closing type of mechanisms proceeds by free amino acid nucleophilic attack at C2 of the quinazoline ring and the consequent ring opening giving intermediate III. The aryl group at position 2 of intermediate II (phenyl group



SCHEME 4 Preparation of 6-aryl-2,3-dihydro-4*H*-pyrimido[1,2-*c*]quinazolin-4-ones **12a-d**, 5-arylimidazo[1,2-*c*]quinazolin-3(2*H*)-ones **13a-d**, and 5-aryl-2-methylimidazo[1,2-*c*]quinazolin-3(2*H*)-ones **14a-d**

or chlorophenyl groups) has the advantage to facilitate the previous Dimroth rearrangement; however, the presence of phenyl ring attached with electron donating group (MeO) specially at position 4 will decrease the electrophilicity of C2 of the quinazoline ring in intermediate II and prohibit the dimroth rearrangement. The following step is tautomerization together with amino-imino groups flipping and gave IV. Next, an amino group attacks at the amidine function group to give methyl [(2-phenylquinazolin-4-yl) amino] acetate V; this structure is formed in the case of benzyl amine and γ -amino butyric acid methyl ester hydrochloride reaction with benzimidoyl chlorides **9a-d** to afford **7a-d** and **11a-d**, respectively. The reaction continues and the intermediate V reveals NH group at position 3 of the quinazoline ring capable of attacking the amino acid ester group to finally give the expected product **13a** (Scheme 5). Similar Dimroth rearrangement results were obtained as reported in literature.^[13-17]

3 | EXPERIMENTAL SECTION


3.1 | General procedures

Solvents were purified and dried by standard procedures. The boiling range of the petroleum ether used was 40°C to 60°C for thin-layer chromatography (TLC) silica gel

60 F₂₅₄ plastic plates (E. Merck, layer thickness, 0.2 mm) were used, detected by UV absorption. The solvent system used was ethyl acetate- pet ether 3:1. Elemental analyses were performed on a *Flash EA-1112* instrument at the Microanalytical Laboratory, Faculty of Science, Suez Canal University, Ismailia, Egypt. Melting points were determined on a Buchi 510 melting-point apparatus, and the values are uncorrected. ¹H and ¹³C NMR spectra were recorded at 400 and 75.5 MHz, respectively, on a Bruker AC 400 in CDCl₃ and DMSO-*d*₆ solution with tetramethylsilane as an internal standard. The NMR analyses were performed at the Chemistry Department, Sohag University, Sohag, Egypt. The starting substituted *N*-(2-cyanophenyl)benzamides **8a-d** were prepared according to the reported method.^[18] Also, starting compounds **1-6** were prepared according to reported literature.^[11,12]

3.1.1 | General procedures for preparation of 4-chloro-2-aryl-3,4-dihydroquinazolines **6a-d**

Phosphoryl chloride (30 mL) was added to quinazolin-4-one derivatives **5a-d** (20 mmol); the reaction mixture was stirred at 5°C for 0.5 hour and then refluxed for 6 hours. The reaction mixture was evaporated under reduced pressure, cooled, and dissolved in 20 mL of



SCHEME 5 Rational preparation of 5-phenylimidazo[1,2-c]quinazolin-3(2H)-one **13a**

methylene chloride. The methylene chloride solution was washed several times with ice-cold ammonia solution 5% (20 mL) then dried over sodium sulfate. The methylene chloride solution was filtered, evaporated, and gave chloroquinazoline derivatives **6a-d** in a pure state and was used without further purification.^[11,12]

3.1.2 | General procedure for the preparation of *N*-alkyl-2-arylquinazolin-4-amines **7a-d** and **10b**

Method A

A mixture of 4-chloro-2-aryl-3,4-dihydro-quinazolines **6a-d** (1.0 mmol) and the appropriate amine, benzyl

amine or allyl amine, were dissolved in DMF and were heated at 100°C for 12 hours. The reaction mixture was cooled and poured over H₂O to give thick white precipitate from the crude product. The reaction mixture was filtered and was crystallized from ethanol to give *N*-alkyl-2-arylquinazolin-4-amine **7a-d** in good yield.

Method B

A mixture of substituted *N*-(2-cyanophenyl) benzamides **8a-d** (1.0 mmol) and thionyl chloride (10 mL) was heated at 70°C for 8 hours. The thionyl chloride was removed under reduced pressure, and the residue was heated at 120°C under reduced pressure (50 mmHg) for 4 extra hours to give a yellowish oil of substituted *N*-(2-cyanophenyl) benzimidoyl chlorides **9a-d**, which

was not further purified. The crude oil was cooled and dissolved in dry acetonitrile; to this, acetonitrile solution was added to the appropriate amine (2.0 mmol), benzyl amine or allyl amine. The reaction mixture was refluxed for 12 hours, and the acetonitrile solvent was evaporated under reduced pressure. The crude product was crystallized from ethanol to give the pure product **7a-d** and **10b** in excellent yields.

N-Benzyl-2-phenylquinazolin-4-amine (7a)

Method A: 0.24 g, yield 78%; Method B: 0.20 g, yield 65%. White crystals, mp 156°C to 157°C. ¹H NMR spectrum, (400 MHz, CDCl₃), δ, ppm (*J*, Hz): 8.63 (2H, d, *J* = 8.0, ArH); 7.99 (1H, d, *J* = 8.0, ArH); 7.75-7.70 (2H, m, ArH); 7.54-7.48 (5H, m, ArH); 7.42-7.34 (4H, m, ArH); 6.13 (1H, bs, NH); 5.03 (2H, d, *J* = 6.0, NHCH₂). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 159.3 (C=N); 159.0 (C=N); 150.1 (C_q); 138.6 (C_q); 135.7 (C_q); 132.7 (CH_{Ar}); 131.5 (CH_{Ar}); 129.6 (CH_{Ar}); 128.5 (CH_{Ar}); 128.2 (CH_{Ar}); 128.1 (CH_{Ar}); 127.9 (CH_{Ar}); 127.4 (CH_{Ar}); 125.6 (CH_{Ar}); 120.4 (CH_{Ar}); 113.9 (C_q); 45.7 (NHCH₂). Anal. calcd. for C₂₁H₁₇N₃ (311.4): C, 81.00; H, 5.50; N, 13.49. Found: C, 80.85; H, 5.47; N, 13.32.

N-Benzyl-2-(4-chlorophenyl)quinazolin-4-amine (7b)

Method A: 0.24 g, yield 69%; Method B: 0.19 g, yield 56%. White crystals, mp 150°C to 152°C. ¹H NMR spectrum, (400 MHz, CDCl₃), δ, ppm (*J*, Hz): 8.55 (2H, d, *J* = 8.0, ArH); 7.95 (1H, d, *J* = 8.0, ArH); 7.76 (1H, t, *J* = 8.0, ArH); 7.70 (1H, d, *J* = 8.0, ArH); 7.49-7.33 (8H, m, ArH); 5.99 (1H, bs, NH); 5.02 (2H, d, *J* = 6.0, NHCH₂). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 159.4 (C=N); 159.2 (C=N); 150.6 (C_q); 138.6 (C_q); 136.2 (C_q); 132.7 (CH_{Ar}); 129.8 (CH_{Ar}); 129.0 (CH_{Ar}); 128.9 (CH_{Ar}); 128.4 (CH_{Ar}); 128.0 (CH_{Ar}); 127.4 (CH_{Ar}); 125.6 (CH_{Ar}); 120.4 (CH_{Ar}); 113.6 (C_q); 45.4 (NHCH₂). Anal. calcd. for C₂₁H₁₆ClN₃ (345.8): C, 72.93; H, 4.66; N, 12.15. Found: C, 72.81; H, 4.62; N, 12.13.

N-Benzyl-2-(3-chlorophenyl)quinazolin-4-amine (7c)

Method A: 0.17 g, yield 49%; Method B: 0.24 g, yield 70%. White crystals, mp 115°C to 116°C. ¹H NMR spectrum, (400 MHz, CDCl₃), δ, ppm (*J*, Hz): 8.60 (1H, s, ArH); 8.49 (1H, d, *J* = 8.0, ArH); 7.98 (1H, d, *J* = 8.0, ArH); 7.77-7.71 (2H, m, ArH); 7.49-7.35 (8H, m, ArH); 6.16 (1H, bs, NH); 4.99 (2H, d, *J* = 6.0, NHCH₂). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 159.5 (C=N); 159.1 (C=N); 149.9 (C_q); 140.4 (C_q); 138.4 (C_q); 134.4 (C_q); 132.8 (CH_{Ar}); 130.2 (CH_{Ar}); 129.5 (CH_{Ar}); 128.9 (CH_{Ar}); 128.6 (CH_{Ar}); 128.1 (CH_{Ar}); 127.7 (CH_{Ar}); 126.6 (CH_{Ar}); 125.9 (CH_{Ar}); 120.7 (CH_{Ar}); 113.6 (C_q); 45.5 (NHCH₂). Anal. calcd. for C₂₁H₁₆ClN₃ (345.8): C, 72.93; H, 4.66; N, 12.15. Found: C, 72.71; H, 4.54; N, 12.01.

N-Benzyl-2-(2-chlorophenyl)quinazolin-4-amine (7d)

Method A: 0.13 g, yield 39%; Method B: 0.18 g, yield 51%. White crystals, mp 116-117°C. ¹H NMR spectrum, (400 MHz, CDCl₃), δ, ppm (*J*, Hz): 8.51 (1H, s, ArH); 7.97 (1H, d, *J* = 8.0, ArH); 7.78 (1H, t, *J* = 8.0, ArH); 7.71 (1H, d, *J* = 8.0, ArH); 7.51-7.30 (9H, m, ArH); 6.03 (1H, bs, NH); 5.02 (2H, d, *J* = 6.0, NHCH₂). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 160.8 (C=N); 159.5 (C=N); 147.6 (C_q); 138.2 (C_q); 133.3 (C_q); 132.9 (CH_{Ar}); 131.6 (CH_{Ar}); 130.5 (CH_{Ar}); 130.3 (CH_{Ar}); 128.7 (CH_{Ar}); 128.3 (CH_{Ar}); 127.6 (CH_{Ar}); 126.9 (CH_{Ar}); 126.6 (CH_{Ar}); 121.6 (CH_{Ar}); 113.0 (C_q); 45.4 (NHCH₂). Anal. calcd. for C₂₁H₁₆ClN₃ (345.8): C, 72.93; H, 4.66; N, 12.15. Found: C, 72.88; H, 4.62; N, 12.02.

N-Allyl-2-(4-chlorophenyl)quinazolin-4-amine (10b)

Method A: 0.25 g, yield 72%; Method B: 0.23 g, yield 69%. White crystals, mp 101°C to 102°C. ¹H NMR spectrum, (400 MHz, CDCl₃), δ, ppm (*J*, Hz): 8.60 (1H, d, *J* = 8.0, ArH); 8.56 (1H, d, *J* = 8.0, ArH); 7.91 (1H, d, *J* = 8.0, ArH); 7.72 (1H, d, *J* = 8.0, ArH); 7.67 (1H, t, *J* = 8.0, ArH); 7.53 (1H, d, *J* = 8.0, ArH); 7.45 (1H, d, *J* = 8.0, ArH); 7.40 (1H, t, *J* = 8.0, ArH); 7.25 (1H, bs, NH); 6.15-6.07 (1H, m, CH); 5.39 (1H, d, *J* = 16.0, CH₂); 5.28 (1H, d, *J* = 12.0, CH₂); 4.48-4.46 (2H, m, NHCH₂). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ, ppm: 164.4 (C=N); 159.6 (C=N); 140.5 (C_q); 139.1 (C_q); 134.9 (CH); 132.2 (CH_{Ar}); 130.4 (C_q); 129.4 (CH_{Ar}); 128.9 (CH_{Ar}); 128.6 (CH_{Ar}); 124.5 (CH_{Ar}); 121.2 (CH_{Ar}); 117.7 (CH₂); 116.4 (C_q); 44.2 (NHCH₂). Anal. calcd. for C₁₇H₁₄ClN₃ (295.8): C, 69.04; H, 4.77; N, 14.21. Found: C, 68.86; H, 4.53; N, 14.18.

3.1.3 | General procedure for the preparation of methyl 4-((2-arylquinazolin-4-yl)amino) butanoates **11a-d**

A mixture of substituted *N*-(2-cyanophenyl) benzamides **8a-d** (1.0 mmol) and thionyl chloride (10 mL) was heated at 70°C for 8 hours. The thionyl chloride was removed under reduced pressure, and the residue was heated at 120°C under reduced pressure (50 mmHg) for 4 extra hours to give a yellowish oil of substituted *N*-(2-cyanophenyl) benzimidoyl chlorides **9a-d**. The crude oil was cooled and dissolved in dry acetonitrile; to this, acetonitrile solution was added to a solution of γ -aminobutyric acid methyl ester hydrochloride (1.0 mmol) and triethyl ethylamine (2.0 mmol) in acetonitrile. The reaction mixture was refluxed for 12 hours, and the acetonitrile solvent was evaporated under reduced pressure. The crude product was crystallized from ethanol to give the pure methyl 4-((2-arylquinazolin-4-yl)amino) butanoates **11a-d**.

Methyl 4-((2-phenylquinazolin-4-yl)amino) butanoate (11a)

0.20 g, yield 63%. Whitish oil. ^1H NMR spectrum, (400 MHz, CDCl_3), δ , ppm (J , Hz): 8.60 (2H, d, $J = 8.0$, ArH); 8.03 (1H, d, $J = 8.0$, ArH); 7.85 (1H, d, $J = 8.0$, ArH); 7.72 (1H, t, $J = 8.0$, ArH); 7.57-7.49 (3H, m, ArH); 7.42 (1H, t, $J = 8.0$, ArH); 6.77 (1H, bs, NH); 3.90 (2H, q, $J = 6.0$, NHCH_2); 3.68 (3H, s, OCH_3); 2.56 (2H, t, $J = 6.0$, CH_2CO); 2.21-2.14 (2H, m, CH_2). ^{13}C NMR spectrum, (75.0 MHz, CDCl_3), δ , ppm: 174.4 (C=O); 159.9 (C=N); 159.7 (C=N); 147.7 (C_q); 137.0 (C_q); 133.1 (CH_{Ar}); 130.9 (CH_{Ar}); 128.7 (CH_{Ar}); 128.4 (CH_{Ar}); 126.7 (CH_{Ar}); 126.0 (CH_{Ar}); 121.6 (CH_{Ar}); 113.4 (C_q); 51.8 (OCH_3); 41.2 (NHCH_2); 31.9 (CH_2CO); 24.1 (CH_2). Anal. calcd. for $\text{C}_{19}\text{H}_{19}\text{N}_3\text{O}_2$ (321.4): C, 71.01; H, 5.96; N, 13.08. Found: C, 70.83; H, 5.87; N, 13.01.

Methyl 4-((2-(4-chlorophenyl)quinazolin-4-yl)amino) butanoate (11b)

0.27 g, yield 75%. White crystals, mp 110°C to 112°C. ^1H NMR spectrum, (400 MHz, CDCl_3), δ , ppm (J , Hz): 8.57 (2H, d, $J = 8.0$, ArH); 7.98 (1H, d, $J = 8.0$, ArH); 7.81-7.63 (2H, m, ArH); 7.58-7.50 (3H, m, ArH); 6.56 (1H, bs, NH); 3.82 (2H, q, $J = 6.0$, NHCH_2); 3.66 (3H, s, OCH_3); 2.51 (2H, t, $J = 6.0$, CH_2CO); 2.16-2.08 (2H, m, CH_2). ^{13}C NMR spectrum, (75.0 MHz, CDCl_3), δ , ppm: 174.4 (C=O); 159.6 (C=N); 159.2 (C=N); 149.0 (C_q); 134.4 (C_q); 132.9 (CH_{Ar}); 130.3 (CH_{Ar}); 129.5 (CH_{Ar}); 128.6 (CH_{Ar}); 127.9 (CH_{Ar}); 126.7 (CH_{Ar}); 126.0 (CH_{Ar}); 114.1 (C_q); 52.0 (OCH_3); 43.3 (NHCH_2); 30.5 (CH_2CO); 22.5 (CH_2). Anal. calcd. for $\text{C}_{19}\text{H}_{18}\text{ClN}_3\text{O}_2$ (355.8): C, 64.14; H, 5.10; N, 11.81. Found: C, 63.93; H, 4.92; N, 11.76.

Methyl 4-((2-(3-chlorophenyl)quinazolin-4-yl)amino) butanoate (11c)

0.30 g, yield 84%. White crystals, mp 95°C to 96°C. ^1H NMR spectrum, (400 MHz, CDCl_3), δ , ppm (J , Hz): 8.57 (1H, s, ArH); 8.48 (1H, d, $J = 8.0$, ArH); 7.95 (1H, d, $J = 8.0$, ArH); 7.78 (1H, d, $J = 8.0$, ArH); 7.73 (1H, t, $J = 8.0$, ArH); 7.46-7.40 (3H, m, ArH); 6.52 (1H, bs, NH); 3.85 (2H, q, $J = 6.0$, NHCH_2); 3.69 (3H, s, OCH_3); 2.56 (2H, t, $J = 6.0$, CH_2CO); 2.17-2.12 (2H, m, CH_2). ^{13}C NMR spectrum, (75.0 MHz, CDCl_3), δ , ppm: 174.6 (C=O); 159.8 (C=N); 158.8 (C=N); 149.0 (C_q); 140.0 (C_q); 134.4.0 (C_q); 132.9 (CH_{Ar}); 130.3 (CH_{Ar}); 129.5 (CH_{Ar}); 128.6 (CH_{Ar}); 127.9 (CH_{Ar}); 126.7 (CH_{Ar}); 126.0 (CH_{Ar}); 121.1 (CH_{Ar}); 113.7 (C_q); 51.8 (OCH_3); 41.3 (NHCH_2); 32.0 (CH_2CO); 24.0 (CH_2). Anal. calcd. for $\text{C}_{19}\text{H}_{18}\text{ClN}_3\text{O}_2$ (355.8): C, 64.14; H, 5.10; N, 11.81. Found: C, 63.95; H, 4.84; N, 11.63.

Methyl 4-((2-(2-chlorophenyl)quinazolin-4-yl)amino) butanoate (11d)

0.22 g, yield 62%. White crystals, mp 150°C to 151°C. ^1H NMR spectrum, (400 MHz, CDCl_3), δ , ppm (J , Hz): 8.54

(1H, d, $J = 8.0$, ArH); 7.96 (1H, d, $J = 8.0$, ArH); 7.75 (1H, d, $J = 8.0$, ArH); 7.71 (1H, t, $J = 8.0$, ArH); 7.49-7.39 (4H, m, ArH); 6.61 (1H, bs, NH); 3.89 (2H, q, $J = 6.0$, NHCH_2); 3.61 (3H, s, OCH_3); 2.54 (2H, t, $J = 6.0$, CH_2CO); 2.16-2.09 (2H, m, CH_2). Anal. calcd. for $\text{C}_{19}\text{H}_{18}\text{ClN}_3\text{O}_2$ (355.8): C, 64.14; H, 5.10; N, 11.81. Found: C, 64.03; H, 5.07; N, 11.63.

3.1.4 | General procedure for the preparation of 6-aryl-2,3-dihydro-4H-pyrimido[1,2-c]quinazolin-4-ones 12a-d

Compounds 6-aryl-2,3-dihydro-4H-pyrimido[1,2-c]quinazolin-4-ones **12a-d** were prepared according to the prescribed method for the preparation of methyl 4-((2-arylquinazolin-4-yl)amino) butanoates **11a-d** using β -alanine methyl ester hydrochloride instead of γ -aminobutyric acid methyl ester hydrochloride.

6-Phenyl-2,3-dihydro-4H-pyrimido[1,2-c]quinazolin-4-one (12a)

0.16 g, yield 58%. White crystals, mp 230°C to 231°C. ^1H NMR spectrum, (400 MHz, CDCl_3), δ , ppm (J , Hz): 8.68 (1H, d, $J = 8.0$, ArH); 7.85 (1H, t, $J = 8.0$, ArH); 7.77 (1H, d, $J = 8.0$, ArH); 7.68-7.53 (6H, m, ArH); 4.21 (2H, q, $J = 6.0$, NCH_2); 2.71 (2H, q, $J = 6.0$, CH_2CO). ^{13}C NMR spectrum, (75.0 MHz, CDCl_3), δ , ppm: 175.4 (C=O); 157.7 (C=N); 153.1 (C=N); 146.1 (C_q); 135.5 (CH_{Ar}); 133.8 (C_q); 130.7 (CH_{Ar}); 129.2 (CH_{Ar}); 128.3 (CH_{Ar}); 128.1 (CH_{Ar}); 127.5 (CH_{Ar}); 127.3 (CH_{Ar}); 119.6 (C_q); 46.7 (NCH_2); 29.7 (CH_2CO). Anal. calcd. for $\text{C}_{17}\text{H}_{13}\text{N}_3\text{O}$ (275.3): C, 74.17; H, 4.76; N, 15.26. Found: C, 74.05; H, 4.76; N, 15.18.

6-(3-Chlorophenyl)-2,3-dihydro-4H-pyrimido[1,2-c]quinazolin-4-one (12b)

0.23 g, yield 74%. White crystals, mp 178°C to 179°C. ^1H NMR spectrum, (400 MHz, CDCl_3), δ , ppm (J , Hz): 8.65 (1H, d, $J = 8.0$, ArH); 7.84 (1H, t, $J = 8.0$, ArH); 7.74 (1H, d, $J = 8.0$, ArH); 7.60-7.52 (5H, m, ArH); 4.21 (2H, q, $J = 6.0$, NCH_2); 2.71 (2H, q, $J = 6.0$, CH_2CO). ^{13}C NMR spectrum, (75.0 MHz, CDCl_3), δ , ppm: 175.2 (C=O); 157.6 (C=N); 152.1 (C_q); 145.9 (C_q); 137.2 (C_q); 135.5 (CH_{Ar}); 132.1 (C_q); 129.6 (CH_{Ar}); 129.5 (CH_{Ar}); 128.5 (CH_{Ar}); 127.5 (CH_{Ar}); 127.3 (CH_{Ar}); 119.6 (C_q); 46.7 (NCH_2); 29.7 (CH_2CO). Anal. calcd. for $\text{C}_{17}\text{H}_{12}\text{ClN}_3\text{O}$ (309.8): C, 65.92; H, 3.91; N, 13.57. Found: C, 65.83; H, 3.87; N, 13.46.

6-(3-Chlorophenyl)-2,3-dihydro-4H-pyrimido[1,2-c]quinazolin-4-one (12c)

0.22 g, yield 70%. White crystals, mp 210°C to 211°C. ^1H NMR spectrum, (400 MHz, CDCl_3), δ , ppm (J , Hz): 8.64 (1H, d, $J = 8.0$, ArH); 7.84 (1H, t, $J = 8.0$, ArH); 7.74 (1H, d,

$J = 8.0$, ArH); 7.64 (1H, s, $J = 8.0$, ArH); 7.60-7.46 (4H, m, ArH); 4.21 (2H, q, $J = 6.0$, NCH₂); 2.72 (2H, q, $J = 6.0$, CH₂CO). Anal. calcd. for C₁₇H₁₂ClN₃O (309.8): C, 65.92; H, 3.91; N, 13.57. Found: C, 65.78; H, 3.83; N, 13.45.

6-(2-Chlorophenyl)-2,3-dihydro-4H-pyrimido[1,2-c]quinazolin-4-one (12d)

0.17 g, yield 56%. White crystals, mp 178°C to 179°C. ¹H NMR spectrum, (400 MHz, CDCl₃), δ , ppm (J , Hz): 8.66 (1H, d, $J = 8.0$, ArH); 7.85 (1H, t, $J = 8.0$, ArH); 7.72 (1H, d, $J = 8.0$, ArH); 7.61 (1H, d, $J = 8.0$, ArH); 7.63-7.52 (4H, m, ArH); 4.21 (2H, q, $J = 6.0$, NCH₂); 2.73 (2H, q, $J = 6.0$, CH₂CO). Anal. calcd. for C₁₇H₁₂ClN₃O (309.8): C, 65.92; H, 3.91; N, 13.57. Found: C, 65.79; H, 3.83; N, 13.41.

3.1.5 | General procedure for the preparation of 5-aryl-2-substitutedimidazo[1,2-c]quinazolin-3(2H)-ones 13a-d and 14a-d

Compounds 5-arylimidazo[1,2-c]quinazolin-3(2H)-ones **13a-d** and 5-aryl-2-methyl imidazo[1,2-c]quinazolin-3(2H)-ones **14a-d** were prepared according to the prescribed method for the preparation of methyl 4-((2-arylquinazolin-4-yl)amino) butanoates **11a-d** using glycine methyl ester hydrochloride or L-alanine methyl ester hydrochloride, respectively instead of γ -aminobutyric acid methyl ester hydrochloride.

5-Phenylimidazo[1,2-c]quinazolin-3(2H)-one (13a)

0.22 g, yield 86%. White crystals, mp 236°C to 237°C. ¹H NMR spectrum, (400 MHz, CDCl₃), δ , ppm (J , Hz): 8.47 (1H, d, $J = 8.0$, ArH); 7.93 (1H, t, $J = 8.0$, ArH); 7.89 (1H, d, $J = 8.0$, ArH); 7.75 (2H, d, $J = 8.0$, ArH); 7.68-7.61 (4H, m, ArH); 4.56 (2H, s, CH₂). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ , ppm: 185.7 (C=O); 171.2 (C=N); 159.3 (C=N); 150.1 (C_q); 147.0 (CH_{Ar}); 136.5 (C_q); 133.8 (CH_{Ar}); 133.1 (CH_{Ar}); 131.0 (CH_{Ar}); 129.5 (CH_{Ar}); 128.0 (CH_{Ar}); 127.2 (CH_{Ar}); 125.8 (CH_{Ar}); 115.4 (C_q); 52.8 (CH₂). Anal. calcd. for C₁₆H₁₁N₃O (261.3): C, 73.55; H, 4.24; N, 16.08. Found: C, 73.44; H, 4.15; N, 15.86.

5-(4-Chlorophenyl)imidazo[1,2-c]quinazolin-3(2H)-one (13b)

0.22 g, yield 74%. White crystals, mp 206°C to 207°C. ¹H NMR spectrum, (400 MHz, CDCl₃), δ , ppm (J , Hz): 8.46 (1H, d, $J = 8.0$, ArH); 7.93 (1H, t, $J = 8.0$, ArH); 7.87 (1H, d, $J = 8.0$, ArH); 7.74 (2H, d, $J = 8.0$, ArH); 7.64 (1H, t, $J = 8.0$, ArH); 7.59 (2H, d, $J = 8.0$, ArH); 4.55 (2H, s, CH₂). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ , ppm: 186.6 (C=O); 171.0 (C=N); 159.8 (C=N); 150.5 (C_q); 145.4 (CH_{Ar}); 136.3 (C_q); 133.4 (C_q); 133.1 (CH_{Ar}); 131.7

(CH_{Ar}); 129.5 (CH_{Ar}); 128.6 (CH_{Ar}); 127.5 (CH_{Ar}); 125.5 (CH_{Ar}); 115.2 (C_q); 53.5 (CH₂). Anal. calcd. for C₁₆H₁₀ClN₃O (295.7): C, 64.98; H, 3.41; N, 14.21. Found: C, 64.82; H, 3.38; N, 14.04.

5-(3-Chlorophenyl)imidazo[1,2-c]quinazolin-3(2H)-one (13c)

0.18 g, yield 62%. White crystals, mp 214°C to 215°C. ¹H NMR spectrum, (400 MHz, DMSO-*d*₆), δ , ppm (J , Hz): 8.27 (1H, d, $J = 8.0$, ArH); 8.02 (1H, t, $J = 8.0$, ArH); 7.94 (1H, s, ArH); 7.85 (2H, t, $J = 8.0$, ArH); 7.75-7.69 (2H, m, ArH); 7.62 (1H, t, $J = 8.0$, ArH); 4.71(2H, s, CH₂). ¹³C NMR spectrum, (75.0 MHz, DMSO-*d*₆), δ , ppm: 185.1 (C=O); 171.3 (C=N); 150.2 (C=N); 147.3 (C_q); 136.8 (CH_{Ar}); 135.7 (C_q); 133.8 (C_q); 131.3 (CH_{Ar}); 131.1 (CH_{Ar}); 128.8 (CH_{Ar}); 128.3 (CH_{Ar}); 127.6 (CH_{Ar}); 127.1 (CH_{Ar}); 115.8 (C_q); 53.9 (NCH₂). Anal. calcd. for C₁₆H₁₀ClN₃O (295.7): C, 64.98; H, 3.41; N, 14.21. Found: C, 64.82; H, 3.29; N, 14.06.

5-(2-Chlorophenyl)imidazo[1,2-c]quinazolin-3(2H)-one (13d)

0.18 g, yield 60%. White crystals, mp 181°C to 182°C. ¹H NMR spectrum, (400 MHz, DMSO), δ , ppm (J , Hz): 8.32 (1H, d, $J = 8.0$, ArH); 8.05 (1H, t, $J = 8.0$, ArH); 7.86 (1H, d, $J = 8.0$, ArH); 7.79-7.56 (5H, m, ArH); 4.38 (2H, s, CH₂). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ , ppm: 183.8 (C=O); 171.1 (C=N); 148.7 (C_q); 147.2 (C_q); 136.5 (CH_{Ar}); 132.4 (CH_{Ar}); 131.9 (C_q); 130.4 (CH_{Ar}); 129.8 (CH_{Ar}); 128.8 (CH_{Ar}); 128.4 (CH_{Ar}); 128.0 (CH_{Ar}); 127.6 (CH_{Ar}); 122.8 (CH_{Ar}); 115.8 (C_q); 51.9 (NCH₂). Anal. calcd. for C₁₆H₁₀ClN₃O (295.7): C, 64.98; H, 3.41; N, 14.21. Found: C, 64.65; H, 3.29; N, 14.03.

2-Methyl-5-phenylimidazo[1,2-c]quinazolin-3(2H)-one (14a)

0.13 g, yield 49%. White crystals, mp 230°C to 231°C. ¹H NMR spectrum, (400 MHz, CDCl₃), δ , ppm (J , Hz): 8.40 (1H, d, $J = 8.0$, ArH); 7.90-7.81 (2H, m, ArH); 7.75-7.73 (2H, m, ArH); 7.63-7.56 (4H, m, ArH); 4.79 (1H, q, $J = 6.0$, CH); 1.17 (3H, d, $J = 6.0$, CH₃). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ , ppm: 188.0 (C=O); 170.8 (C=N); 159.0 (C=N); 150.8 (C_q); 147.3 (CH_{Ar}); 136.5 (C_q); 134.1 (CH_{Ar}); 133.3 (CH_{Ar}); 131.3 (CH_{Ar}); 129.4 (CH_{Ar}); 128.4 (CH_{Ar}); 127.6 (CH_{Ar}); 126.4 (CH_{Ar}); 115.6 (C_q); 59.9 (CH); 16.5 (CH₃). Anal. calcd. for C₁₇H₁₃N₃O (275.3): C, 74.17; H, 4.76; N, 15.26. Found: C, 74.11; H, 4.64; N, 15.17.

5-(4-Chlorophenyl)-2-methylimidazo[1,2-c]quinazolin-3(2H)-one (14b)

0.22 g, yield 71%. White crystals, mp 225°C to 226°C. ¹H NMR spectrum, (400 MHz, CDCl₃), δ , ppm (J , Hz): 8.57 (1H, d, $J = 8.0$, ArH); 7.96 (1H, t, $J = 8.0$, ArH); 7.89 (1H, d, $J = 8.0$, ArH); 7.76 (2H, d, $J = 8.0$, ArH); 7.67 (1H, t,

$J = 8.0$, ArH); 7.61 (2H, d, $J = 8.0$, ArH); 4.92 (1H, q, $J = 6.0$, CH); 1.27 (3H, d, $J = 6.0$, CH₃). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ , ppm: 187.5 (C=O); 171.6 (C=N); 160.2 (C=N); 150.5 (C_q); 145.1 (CH_{Ar}); 135.6 (C_q); 133.1 (C_q); 133.6 (CH_{Ar}); 130.4 (CH_{Ar}); 129.5 (CH_{Ar}); 128.2 (CH_{Ar}); 127.9 (CH_{Ar}); 125.3 (CH_{Ar}); 115.6 (C_q); 59.6 (CH); 16.2 (CH₃). Anal. calcd. for C₁₇H₁₂ClN₃O (309.8): C, 65.92; H, 3.91; N, 13.57. Found: C, 65.87; H, 3.73; N, 13.48.

5-(3-Chlorophenyl)-2-methylimidazo[1,2-c]quinazolin-3(2H)-one (14c)

0.27 g, yield 86%. White crystals, mp 240°C to 241°C. ¹H NMR spectrum, (400 MHz, CDCl₃), δ , ppm (J , Hz): 8.52 (1H, d, $J = 8.0$, ArH); 7.95 (1H, t, $J = 8.0$, ArH); 7.88 (1H, d, $J = 8.0$, ArH); 7.78 (1H, s, ArH); 7.68-7.61 (3H, m, ArH); 7.56 (1H, t, $J = 8.0$, ArH); 4.84 (1H, q, $J = 6.0$, CH); 1.25 (3H, d, $J = 6.0$, CH₃). ¹³C NMR spectrum, (75.0 MHz, DMSO-*d*₆), δ , ppm: 185.3 (C=O); 170.9 (C=N); 150.2 (C=N); 147.3 (C_q); 136.7 (CH_{Ar}); 135.3 (C_q); 133.2 (C_q); 131.3 (CH_{Ar}); 131.0 (CH_{Ar}); 128.9 (CH_{Ar}); 128.6 (CH_{Ar}); 127.7 (CH_{Ar}); 126.8 (CH_{Ar}); 115.5 (C_q); 59.4 (CH); 16.9 (CH₃). Anal. calcd. for C₁₇H₁₂ClN₃O (309.8): C, 65.92; H, 3.91; N, 13.57. Found: C, 65.74; H, 3.79; N, 13.42.

5-(2-Chlorophenyl)-2-methylimidazo[1,2-c]quinazolin-3(2H)-one (14d)

0.15 g, yield 48%. White crystals, mp 150°C to 151°C. ¹H NMR spectrum, (400 MHz, CDCl₃), δ , ppm (J , Hz): 8.49 (1H, d, $J = 8.0$, ArH); 8.10 (1H, t, $J = 8.0$, ArH); 8.00-7.88 (2H, m, ArH); 7.76-7.66 (3H, m, ArH); 7.33 (1H, t, $J = 8.0$, ArH); 5.03 (1H, q, $J = 6.0$, CH); 1.29 (3H, d, $J = 6.0$, CH₃). ¹³C NMR spectrum, (75.0 MHz, CDCl₃), δ , ppm: 184.6 (C=O); 170.4 (C=N); 147.3 (C_q); 147.7 (C_q); 137.0 (CH_{Ar}); 132.9 (CH_{Ar}); 131.3 (C_q); 130.7 (CH_{Ar}); 129.6 (CH_{Ar}); 128.9 (CH_{Ar}); 128.5 (CH_{Ar}); 128.0 (CH_{Ar}); 127.2 (CH_{Ar}); 123.1 (CH_{Ar}); 115.5 (C_q); 59.0 (CH); 16.7 (CH₃). Anal. calcd. for C₁₇H₁₂ClN₃O (309.8): C, 65.92; H, 3.91; N, 13.57. Found: C, 65.82; H, 3.86; N, 13.44.

ORCID

Walid Fathalla  <https://orcid.org/0000-0002-7769-4042>

REFERENCES

- [1] L. F. Tietze, *Chem. Rev.* **1996**, *96*, 115–36.
- [2] H. Ulrich, *The Chemistry of Imidoyl Halides*, Plenum Press, New York **1968**.
- [3] W. Fathalla, M. Čajan, J. Marek, P. Pazdera, *Molecules* **2001**, *6*, 574–87.
- [4] W. Fathalla, P. Pazdera, *ARKIVOC* **2002**, (i), 7.
- [5] W. Fathalla, P. Pazdera, *ARKIVOC* **2007**, (i), 236.
- [6] W. Fathalla, P. Pazdera, *Chem. Heterocycl. Compds.* **2008**, *44*, 1374–8.
- [7] R. Adams, I. Levine, *J. Am. Chem. Soc.* **1923**, *45*, 2373–7.
- [8] O. Meth-Cohn, S. P. Stanforth, *Comp. Org. Syn.* **1991**, *2*, 777.
- [9] J. March, (1985), *Advanced Organic Chemistry: Reactions, Mechanisms, and Structure* (3rd ed.), New York: Wiley, ISBN 0-471-85472-7.
- [10] C. A. G. N. Montalbetti, V. Falque, *Tetrahedron* **2005**, *61*, 10827.
- [11] M. Megahed, W. Fathalla, J. Heterocyclic, *Chem.* **2018**, *55*, 2799.
- [12] M. Megahed, W. Fathalla, J. Heterocyclic, *Chem.* **2018**, *55*, 2809.
- [13] A. Foucourt, C. Dubouilh-Benard, E. Chosson, C. Corbière, C. Buquet, M. Iannelli, B. Leblond, F. Marsais, T. Besson, *Tetrahedron* **2010**, *66*, 4495–502.
- [14] L. Filák, Z. Riedl, O. Egyed, M. Czugler, C. N. Hoang, J. G. Schantl, G. Hajós, *Tetrahedron* **2008**, *64*, 1101–13.
- [15] W. Fathalla, P. Pazdera, *Organic Preparation and procedures international* **2018**, *50*, 385–407.
- [16] W. Fathalla, P. Pazdera, *Chem. Pap.* **2018**, *72*, 209–19.
- [17] W. Fathalla, P. Pazdera, *Tetrahedron* **2017**, *73*, 4573–83.
- [18] K. Osamu, Y. Shigeo, K. Toshiro, *Agric. Biol. Chem.* **1980**, *44*, 2143.

How to cite this article: Fathalla W, Nofal EY, El-Moneim MA. Domino synthesis of pyrimido and imidazoquinazolinones. *J Heterocycl Chem.* 2019;1–9. <https://doi.org/10.1002/jhet.3864>